Comparison of labetalol, propranolol and hydralazine in hypertensive out-patients.
In a randomized cross-over trial the combination labetalol/hydrochlorothiazide was compared with the combination of propranolol/hydralazine/hydrochlorothiazide in 34 uncomplicated hypertensive patients, who were not satisfactorily controlled with hydrochlorothiazide 50 mg alone. The elevated diastolic pressure (D.P.) in 27 patients responded satisfactorily to the labetalol schedule and in 28 patients to the propranolol/hydralazine schedule. No difference was found in the rate of decrease of D.P., nor in the disappearance of hypertension-related complaints. Although the duration of the washout between treatments was at least one month, treatment was significantly more efficacious during the second period. Labetalol pre-treatment especially seemed to enhance the effect of subsequent propranolol/hydralazine administration. Side effects due to therapy were rare and were not related to any particular treatment. The median daily dose of labetalol in responders was 600 mg and that of propranolol/hydralazine 120/60 mg (in both therapies hydrochlorothiazide 50 mg was given in addition). Patients showed a slight preference for the labetalol medication. It is concluded that labetalol/hydrochlorothiazide and propranolol/hydralazine/hydrochlorothiazide are equally satisfactory in the treatment of uncomplicated hypertension.
D000328:Adult; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006830:Hydralazine / Q000008:administration & dosage*; D006973:Hypertension / Q000188:drug therapy*; D007741:Labetalol / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000008:administration & dosage*; D013997:Time Factors
D004983:Ethanolamines; D006830:Hydralazine; D011433:Propranolol; D007741:Labetalol